<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, May 3, 2019 (HealthDay News) — Atenolol is associated with a reduction in incident intermediate- and low-risk prostate cancer (PCa), according to a study presented at the annual meeting of the American Urological Association, held from May 3 to 6 in Chicago.<\/p>\n
Ali Zahalka, M.D., Ph.D., from the Albert Einstein College of Medicine and Montefiore Medical Center in Bronx, New York, and colleagues conducted a retrospective review of men who underwent initial prostate biopsy for any clinical indication between 2006 and 2016 to examine the correlation between use of oral beta-blockers and incident PCa. Data were included for 4,182 men who underwent initial prostate biopsy during the study period.<\/p>\n
Based on preceding prescription refill history, the researchers found that 669 men (16 percent) were included in the beta-blocker cohort; 350 of these men had benign pathology and 319 had PCa. Of all men with PCa on biopsy, 8.1, 25.0, 4.0, and 16.0 percent had high-, intermediate-, low-, and very low-risk PCa. After adjustment for age, prostate-specific antigen, body mass index, socioeconomic status, cardiovascular disease, and race, the beta-blocker atenolol displayed a significant protective effect on incident low-risk and intermediate-risk PCa (odds ratios, 0.55 and 0.11, respectively).<\/p>\n
“Our results, combined with recent results from preclinical models of PCa, provide preliminary support for further research into the use of atenolol as a potential protective pharmacologic agent against de novo PCa or PCa disease progression,” the authors write.<\/p>\n
Abstract<\/a><\/p>\n